Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is composed of 39 amino acids. It is currently being examined in scientific research involving metabolic pathway models.
Additionally, Tirzepatide has potential effects on glucose regulation mechanisms and metabolic signaling.
Experimental observations suggest that the compound may be relevant to investigations of energy balance and mass regulation in preclinical research models.
Tirzepatide is intended strictly for laboratory research. It is not designed, labeled, or approved for diagnostic, therapeutic, or consumable use.
All the products we sell at Neuro Peptides are strictly for research purposes.
In laboratory research models, the compound demonstrates dual activity at receptors commonly associated with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) signaling pathways.
When introduced into controlled research environments, Tirzepatide is observed to bind to these receptors. Researchers have suggested that the compound may target and start intracellular signaling cascades in preclinical research models.
The dual-receptor interaction profile of Tirzepatide allows researchers to investigate how activation of GIP and GLP-1-related signaling pathways may affect peptide-receptor dynamics.
Tirzepatide is being studied for its potential in treating several conditions:
Tirzepatide has shown promise in helping manage blood sugar levels in people with type 2 diabetes. The study is especially investigating the potential of Tirzepatide in participants with type 2 diabetes during the fasting month of Ramadan (Eli Lilly and Company, 2026).
Clinical trials are exploring the use of tirzepatide for weight loss in people with obesity.
An ongoing study is evaluating the efficacy of Tirzepatide for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa. This is a chronic skin condition characterized by painful, inflamed lesions. (Myrick & University of Alabama at Birmingham, 2026)
This rare genetic disorder Wolfram syndrome that usually appear in childhood and cause diabetes, optic atrophy leading to loss of vision, deafness and often diabetes insipidus. Researchers are studying tirzepatide as a potential treatment to delay or even reverse disease progression based on their ability to reduce elevated ER stress in vitro and in vivo. (University Hospital Tübingen, 2022)
A study is looking at how Tirzepatide might affect biomarkers related to breast cancer risk in women with obesity. The primary objective of this clinical trial is to determine the proportion of patients who achieve a 5% or greater reduction in body weight by the end of the study treatment with tirzepatide, during adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer (University of Kansas Medical Center, 2024).
It is studied for GLP-1 receptor activity, insulin signaling, and glucose control pathways.
No. The FDA does not approve this vial, and it is not suitable for human use. It is for laboratory research only.
No. Tirzepatide is a research-grade compound, not a compounded preparation or prescription.
Chemical properties
